These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37702136)

  • 21. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases.
    Lavazais S; Jargosch M; Dupont S; Labéguère F; Menet C; Jagerschmidt C; Ohm F; Kupcsik L; Parent I; Cottereaux C; Marsais F; Oste L; Van de Water A; Christophe T; De Vos S; Fallon P; Lauffer F; Clément-Lacroix P; Eyerich K; Brys R
    Sci Transl Med; 2023 Feb; 15(683):eabj3289. PubMed ID: 36791209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies.
    Bhujbal SP; He W; Hah JM
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IRAK4 exacerbates traumatic brain injury via activation of TAK1 signaling pathway.
    Xu X; Zhi T; Hua L; Jiang K; Chen C
    Exp Neurol; 2022 May; 351():114007. PubMed ID: 35149117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Sishen Wan on dinitrobenzene sulfonic acid-induced ulcerative colitis and its effect on toll-like receptor 2/interleukin-1 receptor-associated kinase-4/nuclear factor-κB signal pathway.
    Zhaohua Z; Rong L; Nana DU; Xiangdong Z
    J Tradit Chin Med; 2022 Aug; 42(4):565-575. PubMed ID: 35848973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological inhibition of IRAK1 attenuates colitis-induced tumorigenesis in mice by inhibiting the inflammatory response and epithelial-mesenchymal transition.
    Feng Z; Duan Z; Shi G; Wang Q; Zhou J; Chen Y
    J Biochem Mol Toxicol; 2021 Sep; 35(9):e22838. PubMed ID: 34273909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).
    McElroy WT
    Expert Opin Ther Pat; 2019 Apr; 29(4):243-259. PubMed ID: 30916602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IRAK4 kinase activity is not required for induction of endotoxin tolerance but contributes to TLR2-mediated tolerance.
    Xiong Y; Pennini M; Vogel SN; Medvedev AE
    J Leukoc Biol; 2013 Aug; 94(2):291-300. PubMed ID: 23695305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).
    Seganish WM
    Expert Opin Ther Pat; 2016 Aug; 26(8):917-32. PubMed ID: 27310003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Innate immune interleukin-1 receptor-associated kinase 4 exacerbates viral myocarditis by reducing CCR5(+) CD11b(+) monocyte migration and impairing interferon production.
    Valaperti A; Nishii M; Liu Y; Naito K; Chan M; Zhang L; Skurk C; Schultheiss HP; Wells GA; Eriksson U; Liu PP
    Circulation; 2013 Oct; 128(14):1542-54. PubMed ID: 24030499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent Progress in the Molecular Recognition and Therapeutic Importance of Interleukin-1 Receptor-Associated Kinase 4.
    Patra MC; Choi S
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27845762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deciphering the intrinsic dynamics of unphosphorylated IRAK4 kinase bound to type I and type II inhibitors.
    Gosu V; Sasidharan S; Saudagar P; Radhakrishnan K; Lee HK; Shin D
    Comput Biol Med; 2023 Jun; 160():106978. PubMed ID: 37172355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis.
    Naeem M; Lee J; Oshi MA; Cao J; Hlaing SP; Im E; Jung Y; Yoo JW
    Acta Biomater; 2020 Oct; 116():368-382. PubMed ID: 32937207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Discovery of 7-Isopropoxy-2-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-
    Evans R; Bolduc PN; Pfaffenbach M; Gao F; May-Dracka T; Fang T; Hopkins BT; Chodaparambil JV; Henry KL; Li P; Metrick C; Nelson A; Trapa P; Thomas A; Burkly L; Peterson EA
    J Med Chem; 2024 Mar; 67(6):4676-4690. PubMed ID: 38467640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral Targeted Delivery by Nanoparticles Enhances Efficacy of an Hsp90 Inhibitor by Reducing Systemic Exposure in Murine Models of Colitis and Colitis-Associated Cancer.
    Yang M; Zhang F; Yang C; Wang L; Sung J; Garg P; Zhang M; Merlin D
    J Crohns Colitis; 2020 Jan; 14(1):130-141. PubMed ID: 31168612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression.
    Li Z; Zhang X; Liu C; Peng Q; Wu Y; Wen Y; Zheng R; Yan Q; Ma J
    J Innate Immun; 2022; 14(4):380-392. PubMed ID: 34724662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. USP13-mediated IRAK4 deubiquitination disrupts the pathological symptoms of lipopolysaccharides-induced sepsis.
    Wang Z; Jiang L; Zhang D; Chen D; Wang L; Xiao D
    Microbes Infect; 2021; 23(9-10):104867. PubMed ID: 34298177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.
    McElroy WT; Tan Z; Ho G; Paliwal S; Li G; Seganish WM; Tulshian D; Tata J; Fischmann TO; Sondey C; Bian H; Bober L; Jackson J; Garlisi CG; Devito K; Fossetta J; Lundell D; Niu X
    ACS Med Chem Lett; 2015 Jun; 6(6):677-82. PubMed ID: 26101573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists.
    Vollmer S; Strickson S; Zhang T; Gray N; Lee KL; Rao VR; Cohen P
    Biochem J; 2017 Jun; 474(12):2027-2038. PubMed ID: 28512203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma.
    Chen Y; Ning Y; Chen Z; Xue Y; Wu Q; Duan W; Ding J; Zhou J; Xie H; Zhang H
    Eur J Med Chem; 2023 Aug; 256():115453. PubMed ID: 37163947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Zhang D; Li L; Jiang H; Knolhoff BL; Lockhart AC; Wang-Gillam A; DeNardo DG; Ruzinova MB; Lim KH
    Clin Cancer Res; 2017 Apr; 23(7):1748-1759. PubMed ID: 27702822
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.